Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases

• Main Author: Yamini, Prashanth
• Other Authors: Dang Thuy Tram
• Format: Final Year Project
• Language: English
• Published: Nanyang Technological University 2024
• Subjects: Business and Management; Engineering; Medicine, Health and Life Sciences; Therapy; Psoriasis; Eczema
• Online Access: https://hdl.handle.net/10356/177425
• Institution: Nanyang Technological University

The objective of this report is to develop and analyse the commercial proposition of “Respon Therapeutics” in the management of chronic inflammatory skin diseases. “Respon Therapeutics” is a proprietary platform precision drug-delivery system developed by Professor Dang’s Laboratory for the management of chronic inflammatory diseases. It can be customised to suitable indications in this domain, having demonstrated clinical promise and commercial potential in the management of arthritis symptoms. There is now an opportunity to expand it to address symptoms of chronic inflammatory skin diseases such as Eczema and Psoriasis. As a first step, it is imperative to develop and validate some conceptualization of Respon that could address a sufficiently significant and lucrative gap in their current treatment landscapes. There were three key deliverables – gap analysis to identify a significant unsolved problem in the treatment pathway, product-market fit to conceive a format in which Respon could address the identified problem, and market analysis to identify and size the optimal entry market for the proposed solution. Each analysis entailed an iterative and tailored process of literature reviews, secondary market research, primary research (stakeholder interviews), as well as independent and collaborative brainstorming. Ultimately, it was established that the elimination of stubborn psoriatic patches was a significant treatment gap, which could be addressed by intradermal delivery of steroids through a novel “Respon Micro-Array Patch”. This would optimally service 18-35 year-old patients of moderate-severe psoriasis in the United States of America, representing an average annual Beachhead market of $2.03Bn.